Business
Voyageur Pharmaceuticals Ltd. Announces Health Canada Approval and Issuance of Product Licenses for MultiXThin Radiographic Barium Contrast
(TheNewswire) Calgary, Alberta - TheNewswire - May 5, 2021 - Voya...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals Ltd. Announces Health Canada Approval and Issuance of Product Licenses for MultiXThin Radiographic Barium Contrast\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n Calgary, Alberta -\n \n \n TheNewswire\n-\n \n \n May 5, 2021 -\n \n \n Voyageur Pharmaceuticals Ltd.\n \n \n (\n \n \n TSXV:VM)\n \n \n (\n \n \n OTC:VYYRF\n \n \n ) (the \"Company\" or\n\"Voyageur\") is pleased to announce that it has received\napproval from Health Canada (HC) for its product,\n \n \n MultiXthin barium sulfate\nsuspension\n \n \n . MultiXthin is specifically designed\n \n \n \n for\n \n \n \n single\ncontrast radiographic examinations of the oesophagus, stomach, and\nsmall bowel to visualize the gastrointestinal (GI) tract in adult and\npediatric patients.\n \n \n \n \n Voyageur has built a suite of barium radiographic\ncontrast media products for global sales and  distribution. The\nfollowing products  have  been\n \n \n licensed\n \n \n :\n \n \n \n \n \n \n - SmoothX – For CT market\n \n \n \n \n - HDX – For Flouroscopy market\n \n \n \n \n - LDX – For fluoroscopy market\n \n \n \n \n - MultiXthin – For Flouroscopy market\n \n \n \n \n \n \n Voyageur is prepared to test its newly-formulated\nproducts under GMP and HC guidelines and  advance to clinical\ntesting. Voyageur plans to ensure that it is creating the highest\nquality products prior to phase one marketing, sales and distribution\nto Canadian, USA and international markets.\n \n \n \n \n Voyageur has begun the process to prepare applications\nfor\n \n \n FDA\n \n \n device registrations. Based on the new regulatory change of\nbarium sulfate being designated as a device, versus its previous\ndesignation as a drug, Voyageur plans to move forward with a marketing\nand sales strategy for the US market.\n \n \n \n \n Further to news releases dated April 13 and 23, 2021,\nthe Company announces that it has closed the first tranche of a\nnon-brokered private placement of common units (\"Common\nUnits\") and flow-through units (\"Flow-Through Units\")\n(the \"Offering\"). The Offering was a combination of (i)\nCommon Units issued at a price of $0.15 per Common Unit and comprised\nof one (1) common share and one (1) common share purchase warrant,\nexercisable at $0.30 for a period of two years from the closing date,\nand (ii) F...